CAH

$215.50-2.09 (-0.96%)

Market OpenAs of Mar 17, 7:12 PM UTC

Cardinal Health, Inc.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$215.50
Potential Downside
42%
Whystock Fair Value$124.92
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Distribution

Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company prov...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$50.71B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
31.05
Beta
Defensive asset. Lower volatility than the S&P 500.
0.62
Div Yield
Strong income play. Yield provides a meaningful total return floor.
94.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.38

Recent News

Investor's Business Daily
Mar 17, 2026

Dow Jones Giant Caterpillar Hits Key Level Amid Stock Market Pullback

Dow Jones giant Caterpillar is trying to find support at a key level amid the ongoing stock market volatility.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 17, 2026

Here's Why You Should Hold Cencora Stock in Your Portfolio for Now

Cencora's strong U.S. growth, MSO strategy, and raised outlook support long-term potential, but competition and customer losses remain key risks.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 17, 2026

KORU Medical Secures EU MDR Certification for Freedom60 Infusion Pump

KRMD secures EU MDR certification for its Freedom60 Infusion Pump, opening broader EU access and boosting adoption of patient-friendly home infusion solutions.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 17, 2026

Senseonics Reports Strong One-Year Real-World Data for Eversense 365

SENS highlights strong one-year real-world data for Eversense 365, reinforcing adherence, glucose control and long-term adoption potential.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 16, 2026

Here's Why You Should Hold DexCom Stock in Your Portfolio for Now

DXCM gains from CGM demand, Medicare coverage expansion and its new G7 15-day sensor, but rising competition and manufacturing investments may pressure margins.

BEARISH
Negative press. News cycle fixated on risk factors or misses.